Economic sovereignty

As part of a study carried out at the request of SIDIV (the French Syndicate for the In Vitro Diagnostics Industry), in order to guide strategic developments in the French IVD sector, Alcimed conducted an overall analysis of the French medical biology market by characterizing the laboratories and other actors in medical biology, as well as their expectations, while anticipating and projecting the expected or possible changes in this market.

This study was conducted from September 2021 to January 2022, and is based on a review of the literature and interviews with medical biology stakeholders, a workshop, and regular exchanges with the steering committee at SIDIV. Our analyses and strategic recommendations were presented to the Healthcare Sector Strategic Committee (CSF), then within the framework of a meeting on the strategic challenges of sovereignty, innovation, and access speed to the IVD sector market in Europe, within the context of the French Presidency of the European Union (FPEU).

Every 6 years, the French Regions draw up master plans to guide the economic development of their territory and to initiate necessary transformations, in order to meet current and future challenges.

The 2022-2028 REDPIIC proposed by the region of Normandy aims to develop and protect its industry, but also offers a distinguishing and resilient development model.

The strategy put in place echoes the themes defined in the S3, co-constructed by Alcimed, the Regional Council, and ADN Normandie, as well as a broad consultation of stakeholders. Alcimed is currently supporting the Normandy Region in the process of developing its future REDPIIC by providing its expertise in the consultation and formalization phases for the operational roadmap.

Alcimed supported the Directorate General for Enterprises (DGE), LEEM, and SICOS by: – Drawing up an inventory of the two targeted business activities in France;

• Analyzing their competitiveness vis-à-vis international supply and demand;
• Developing prospective development scenarios for improving this competitiveness;
• Building an action plan and making recommendations in this respect.

Based on this analysis, Alcimed has made recommendations to support the development of key business activities to ensure the sovereignty of the healthcare industries sector.

From 2011 to 2018, Alcimed was responsible for carrying out, on behalf of the Directorate General of Enterprises (DGE) and the National Agency for Territorial Cohesion (ANCT), strategic audits of industrial projects as part of examining applications for regional planning grants (PAT) and reindustrialization assistance (ARI).

This governmental aid was intended to create value for a territory, either in terms of industrial relocation, product-process innovation, or regional development for the purpose of job creation.

The audits carried out by our teams made it possible to objectivize the decisions to allocate this public funding in the form of subsidies or repayable advances.

Alcimed has helped a French region to build its regional EDIH (European Digital Innovation Hub), which aims to support all SMEs and ETIs in the region to grasp the challenges of AI, cybersecurity and high-performance computing.

To achieve this, we led several working sessions with the project’s stakeholders. We then provided support in formalising the submission file, enabling the offer, model and organisation of this regional hub to be built in conjunction with more than 80 entities in the region.

In the end, the region’s application was accepted, enabling it to obtain a grant to set up the hub.

Alcimed worked with a manufacturer in the energy sector and its strategic teams to meet the challenges of exposure to the supply of critical raw materials and to guide the group’s supply and R&D strategies.

We investigated the external risks linked to the supply and demand of 36 raw materials used by the Group, and then the internal risks linked to the use of these raw materials. In the end, we obtained a complete mapping of the risks, enabling us to identify the critical raw materials.

This project has given the Group a clear view of the materials that are genuinely sensitive to its business, and has enabled it to develop its economic sovereignty.

Biomanufacturing is a real sovereignty issue if we are to control a French industry capable of producing new drugs from start to finish. It was around this challenge that our teams helped a national academic platform to position its offer in line with the expectations of players in the region.

We supported our client by identifying current biomanufacturing practices from the pre-clinical to Phase I stages, with a focus on practices in place abroad, and completed the study by analysing the receptiveness of targets such as manufacturers, academic laboratories and start-ups.

Our work enabled us to validate the relevance of the project in the light of the competitive offer in other countries and the interest expressed by the targets!